Enhanced apoptosis mediates inhibition of EBV-transformed lymphoblastoid cell line proliferation by curcumin

Journal of Surgical Research

Volumn 87, Issue 1, 1999, Pages 1-5

  Ranjan, Dinesh ^a   Johnston, Thomas D ^a   Reddy, Kunam S ^a   Wu, Guanghan ^a   Bondada, Subbarao ^a   Chen, Changguo ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Apoptosis; B cell lymphoma; Curcumin; Lymphoblastoid cell line; PTLD

Indexed keywords

CURCUMIN;

APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CELL COUNT; CELL IMMORTALIZATION; CELL PROLIFERATION; CELL TRANSFORMATION; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; LYMPHOBLASTOID CELL LINE; LYMPHOPROLIFERATIVE DISEASE; NONHUMAN; PRIORITY JOURNAL;

EID: 0032719741     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1006/jsre.1999.5719     Document Type: Article

References (39)

1. Freedman A. S., Nadler L. M. Malignant lymphomas. Isselbacher K. J. Harrison's Principle of Internal Medicine. 1994;1774-1788 McGraw-Hill, New York.
2. Ranjan D., Siquijor A., Johnston T. D., Wu G., Nagabhuskahn M. The effect of curcumin on human B-cell immortalization by Epstein-Barr virus. Am. Surg. 64:1998;47.
3. Ranjan D., Johnston T. D., Wu G., Elliott L., Bondada S., Nagabhushan M. Curcumin blocks cyclosporine A-resistant CD 28 costimulatory pathway of human T cell proliferation. J. Surg. Res. 77:1998;174.
4. Reid S., Cross R., Snow C. Combined Hoechst 33342 and merocyanine 540 staining to examine murine B cell cycle stage, viability and apoptosis. J. Immunol. Methods. 192:1996;43.
5. Moss D. J., Pope J. H. Assay of the infectivity of Epstein-Barr virus by transformation of human leucocytes in vitro. J. Gen. Virol. 17:1972;233.
6. Zeidler R., Meissner P., Eissner G., Lazis S., Hammerschmidt W. Rapid proliferation of B cells from adenoids in response to Epstein-Barr virus infection. Cancer Res. 56:1996;5610.
7. Thomas J. A., Allday M. J., Crawford D. H. Epstein-Barr virus associated lymphoproliferative disorders in immunocompromised individuals. Adv. Cancer Res. 57:1991;329.
8. Fauci A. M., Lane H. C. HIV disease. Isselbacher K. J. Harrison's Principle of Internal Medicine. 1994;1566-1617 McGraw-Hill, New York.
9. Dodd G. D., Greenler D. P., Scharmen R. C. Thoracic and abdominal manifestations of lymphoma occurring in the immunocompromised patient. Radiat. Clin North Am. 30:1992;597.
10. Penn I. The changing patterns of post transplant malignancies. Transplant. Proc. 23:1991;1101.
11. Swerdlow S. H. Post-transplant lymphoproliferative disorders: A morphologic, phenotypic, and genotypic spectrum of disease. Histopathology. 20:1991;373.
12. Thorley-Lawson D. A. Basic virological aspects of Epstein-Barr virus infection. Semin. Hematol. 25:1988;247.
13. Penn I. Immunosuppression and opportunistic tumors: Do viruses play a role. Dammaco F. Immuno. Inconcontri., Advances in Tumor Immunology and Allergic Disorders. 1992;139-162 Edi Ermes, Milan.
14. Oliveri M.-T., Diekmann R. A., Kubo S. H. Low incidence of neoplasia in heart and heart-lung transplant receipients receiving triple-drug immunosuppression. J. Heart Transplant. 9:1990;618.
15. Wang C., Salahudeen A. K. Lipid peroxidation accompanies cyclosporine nephrotoxicity: Effects of vitamin E. Kidney Int. 47:1995;927.
16. Penn I., Brunson M. E. Cancers after cyclosporine therapy. Transplant. Proc. 20:1988;S885.
17. Gordon J., Cairns J. A. Autocrine regulation of normal and malignant B lymphocytes. Adv. Cancer Res. 56:1991;313.
18. Tosato G., Tanner G., Jones K. D. Identification of IL6 as an autocrine growth factor for EBV immortalized B-cell. J. Virol. 64:1990;3033.
19. Rowe M., Peng-Pilon M., Huen D. S. Upregulation of bcl-2 by the Epstein-Barr virus latent membrane protein LMP1: A B-cell-specific response that is delayed relative to NF-κB activation and to induction of cell surface markers. J. Virol. 68:1994;5602.
20. Herrero J. A., Mathew P., Paya C. V. LMP1 activates NF-κB by targeting the inhibitory molecule IκBα J. Virol. 69:1995;2168.
21. Baeuerle P. A. The inducible transcription activator NF-κB: Regulation by distinct protein subunits. Biochem. Biophys. Acta. 1072:1991;63.
22. Kieff E. Epstein-Barr virus and its replication. Fields B. N., Knipe D. M., Howley P. M. Field's Virology. 1996;2397-2446 Lippincott-Raven, Philadelphia.
23. Jones K., Rivera C., Sgadari C., Franklin J., Max E. E., Bhatia K., Tosato G. Infection of human endothelial cells with Epstein-Barr virus. J. Exp. Med. 182:1995;1213.
24. Miyazaki I., Cheung R. K., Dosch H. M. Viral interleukin 10 is critical for the induction of B cell growth transformation by EBV. J. Exp. Med. 178:1993;439.
25. Metzenberg S. Levels of EBV DNA in lymphoblastoid cell lines. J. Virol. 64:1990;437.
26. Govindarajan V. R. Turmeric-Chemistry, technology and quality. Food Sci. Nutr. 13:1980;199.
27. Reddy A. C., Lokesh B. R. Studies on the inhibitory effects of curcumin and eugenol on the formation of reactive oxygen species and the oxidation of ferrous iron. Mol. Cell. Biochem. 137:1994;1.
28. Nagabhushan M., Amonkar A. J., Bhide S. V. Antimutagenicity of curcumins and related compounds: The structural requirement for the antimutagenicity of curcumins. Indian Drugs. 21:1987;91.
29. Nagabhushan M., Johnston T. D., Usha K., Wu G. H., Ranjan D. Spices for chemoprevention of gastroenterological cancers. Tahara E., Sugimachi K., Oohara T. Recent Advances in Gastroenteric Carcinogenesis. 1996;1147-1150 Monduzzi Editore, Bologna.
30. Johnston T. D., Nagabhushahn M., Wu G., Ranjan D. Curcumin in phosphate-buffered saline exhibits liver-preserving properties in an ex-vivo perfusion model. Hepatology. 26:1997;353A.
31. Singh S., Aggarwahl B. B. Activation of transcription factor NF-kappa B is suppressed by curcumin. J. Biol. Chem. 270:1995;24995.
32. Han, S, Chung, S, Ranjan, D, and, Bondada, S. Curcumin causes the growth arrest and apoptosis of B cell lymphoma by downregulation of egr-1, C-myc, Bcl-XL, NF-κB, and p53. Submitted for publication.
33. Yi A. K., Hornback P., Lafrenz D. E., Krieg A. M. CpG DNA rescue of murine B lymphoma cells from anti-IgM induced growth arrest and programmed cell death is associated with increased expression of c-myc and bcl-xL. J. Immunol. 157:1996;4918.
34. McMahon S. B., Monroe J. G. The role of early growth response gene 1 (egr-1) in regulation of the immune response. J. Leukocyte Biol. 60:1996;159.
35. Sonensheim G. E. Down modulation of c-myc expression induces apoptosis of B lymphocyte models of tolerance via clonal deletion. J. Immunol. 158:1997;1994.
36. Chen M. M., Huang H. I., Fenton M. R., Fong D. In vivo inhibition of nitric oxide synthase gene expression by curcumin, a cancer preventive natural product with anti-inflammatory properties. Biochem. Pharmacol. 55:1998;1955.
37. Mannick J. B., Asano K., Izumi K., Kieff E., Stamler J. S. Nitric oxide produced by human B lymphocytes inhibits apoptosis and EBV reactivation. Cell. 79:1994;1137.
38. Ravi R., Bedi A., Fuchs E. J., Bedi A. CD95 (FAS) induced caspase-mediated proteolysis of NF-kappaB. Cancer Res. 58:1998;882.
39. J. Cell. Biochem. 72:1996;72.